公司此前指出，由于PB-119的NDA已获国家药监局受理，公司预期将于不久的将来在中国商业化PB- 119。据悉，派格生物已成功构建覆盖6款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于 代谢性疾病及其并发症的治疗，通过持续创新，内部评估显示多款候选药物兼具"同类首创"(FIC)与"同 类最优"(BIC)的双重价值潜力，为未来市场竞争力奠定坚实基础。 派格生物医药-B(02565)涨超8%，高见52.2港元创新高。截至发稿，涨8.23%，报51.95港元，成交额 1217.4万港元。 消息面上，近日，派格生物披露了PB-718的一项Ib/IIa期临床试验结果。研究显示，经剂量滴定后， 1.6mg剂量的PB-718治疗18周可显著降低肝脏脂肪含量(MRI-PDFF)，较基线变化百分比均值 为-57.14%，最大降幅达62%。值得一提的是，此前司美格鲁肽在MASH二期研究中，其2.4mg剂量治疗 24周后，患者肝脏脂肪含量较基线降低幅度也仅为46.2%。 ...

智通财经APP获悉，派格生物医药-B(02565)涨超8%，高见52.2港元创新高。截至发稿，涨8.23%，报 51.95港元，成交额1217.4万港元。 消息面上，近日，派格生物披露了PB-718的一项Ib/IIa期临床试验结果。研究显示，经剂量滴定后， 1.6mg剂量的PB-718治疗18周可显著降低肝脏脂肪含量(MRI-PDFF)，较基线变化百分比均值 为-57.14%，最大降幅达62%。值得一提的是，此前司美格鲁肽在MASH二期研究中，其2.4mg剂量治疗 24周后，患者肝脏脂肪含量较基线降低幅度也仅为46.2%。 公司此前指出，由于PB-119的NDA已获国家药监局受理，公司预期将于不久的将来在中国商业化PB- 119。据悉，派格生物已成功构建覆盖6款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于 代谢性疾病及其并发症的治疗，通过持续创新，内部评估显示多款候选药物兼具"同类首创"(FIC)与"同 类最优"(BIC)的双重价值潜力，为未来市场竞争力奠定坚实基础。 ...

近年来，全球胰高血糖素样肽-1受体激动剂(GLP-1)类药物赛道热度持续高涨，相关市场也得以加速扩容。2024年GLP-1药物销售收入超500亿美元，今年上 半年明星药物司美格鲁肽又凭借Ozempic、Rybelsus与Wegovy"三驾马车"，以166.32亿美元的销售额超越K药，登顶全球药物销量榜首，再次点燃了全球资本 市场热情。 创新价值的持续释放让派格生物得到了二级市场的积极反馈。9月3日，公司盘中股价触及43.28港元，刷新上市新高，带动公司总市值跃过160亿港元。派格 生物或有机会成为首家千亿市值的港股创新减肥药龙头。 挑战MASH"研发黑洞"，临床价值凸显 作为一家专注于自主研究及开发慢性病创新疗法的生物技术公司，派格生物一直致力于慢性疾病创新前沿疗法的研究。 当下港市GLP-1药物赛道中不乏优质标的。前有银诺医药IPO上市暗盘暴涨270%，后有派格生物医药-B(02565)三个月股价累涨超4倍，均体现出市场投资者 对这一热门赛道的追捧。 经过十几年的发展，公司建立了专有的高效靶点筛选与分子修饰平台(HECTOR )。该创新技术平台主要包括代谢疾病数据收集、药物分子设计平台和化合物 筛选平台三个 ...

挑战MASH"研发黑洞"，临床价值凸显 作为一家专注于自主研究及开发慢性病创新疗法的生物技术公司，派格生物一直致力于慢性疾病创新前沿疗法的研究。 经过十几年的发展，公司建立了专有的高效靶点筛选与分子修饰平台(HECTOR®)。该创新技术平台主要包括代谢疾病数据收集、药物分子设计平台和化合 物筛选平台三个部分，其中药物分子设计平台以派格生物聚乙二醇(PEG)技术为特色，可以延长化合物的半衰期、增强长效疗效、提高化合物的稳定性、降 低免疫原性及减少研究成本。 近年来，全球胰高血糖素样肽-1受体激动剂(GLP-1)类药物赛道热度持续高涨，相关市场也得以加速扩容。2024年GLP-1药物销售收入超500亿美元，今年上 半年明星药物司美格鲁肽又凭借Ozempic、Rybelsus与Wegovy"三驾马车"，以166.32亿美元的销售额超越K药，登顶全球药物销量榜首，再次点燃了全球资本 市场热情。 智通财经APP观察到，当下港市GLP-1药物赛道中不乏优质标的。前有银诺医药IPO上市暗盘暴涨270%，后有派格生物医药-B(02565)三个月股价累涨超4 倍，均体现出市场投资者对这一热门赛道的追捧。 虽然目前港股相关明星标 ...

公司名稱: 派格生物醫藥 ( 杭州 ) 股份有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市股份 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 106,791,193 | RMB | | 1 RMB | | 106,791,193 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 106,791,193 | RMB | | 1 RMB | | 106,791,193 | 本月底法定 ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].

Core Viewpoint - The stock of Peijia Medical (02565) has risen over 7%, reaching a new high of HKD 38.66, following the release of its interim results and the acceptance of its NDA for PB-119 by the National Medical Products Administration of China [1] Financial Performance - The company reported other net income of RMB 178,000 and R&D expenses of RMB 26.294 million, with a loss per share of RMB 0.25 [1] - The trading volume reached HKD 18.8928 million at the time of reporting [1] Product Development and Strategy - Peijia Medical anticipates commercializing PB-119 in China soon, following the acceptance of its NDA [1] - The company has successfully established a pipeline of six investigational drugs targeting chronic diseases [1] - The core strategy focuses on treating metabolic diseases and their complications, with multiple candidate drugs showing dual value potential as "first-in-class" (FIC) and "best-in-class" (BIC) [1]

Core Viewpoint - The stock of Peijia Medical (02565) has risen over 7%, reaching a new high of HKD 38.66, following the release of its interim performance report, indicating positive market sentiment towards the company's future prospects [1] Financial Performance - The company reported other net income of RMB 178,000 and research and development expenses of RMB 26.294 million, with a loss per share of RMB 0.25 [1] Product Development and Commercialization - Peijia Medical's NDA for PB-119 has been accepted by the National Medical Products Administration, with expectations for commercialization in China soon [1] - The company anticipates that post-listing, it will incur costs related to its operations as a public company, with financial performance expected to fluctuate based on the development status of candidate drugs, potential collaboration timelines, and regulatory approval schedules [1] Strategic Focus - The company has successfully established a pipeline matrix covering six investigational drugs targeting chronic diseases [1] - Peijia Medical's core strategy focuses on the treatment of metabolic diseases and their complications, with multiple candidate drugs showing dual value potential as "first-in-class" (FIC) and "best-in-class" (BIC), laying a solid foundation for future market competitiveness [1]

Group 1 - The company announced the resignation of Ms. Chan Wan Mei as the co-company secretary, authorized representative, and legal process agent effective from August 26, 2025 [1] - Mr. Zou Xinglong has been appointed as the new co-company secretary, authorized representative, and legal process agent, effective from August 26, 2025 [1] - Mr. Huang Yifeng will continue to serve as another co-company secretary [1]

董事会进一步宣布，陈女士辞任后，邹醒龙先生(邹先生)已获委任为联席公司秘书，授权代表及法律程 序代理人，自2025年8月26日起生效。黄一峰先生(黄先生)将继续担任另一名联席公司秘书。 派格生物医药-B(02565)发布公告，陈婉梅女士(陈女士)已提呈辞任本公司联席公司秘书(联席公司秘 书)、香港联合交易所有限公司(联交所)证券上市规则(上市规则)第3.05条项下的授权代表(授权代表)及 根据上市规则第19A.13(2)条及香港法例第622章公司条例第16部所规定代表本公司于香港接收法律程序 文件及通知的代表(法律程序代理人)，自2025年8月26日起生效。 ...